Search results for the GEO ID: GSE6914  |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM159355 | GPL96 |
|
Calu3-Parental_1
|
Calu3 human non-small lung cancer cells, parental (ATCC)
|
Morphology: epithelial, Organ: lung, Disease: adenocarcinoma (pleural effusion), Gender: male, Ethnicity: caucasian
|
parental Calu3 cells, no treatment
|
| Sample_geo_accession | GSM159355
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | American Type Culture Collection (ATCC)
| | Sample_treatment_protocol_ch1 | parental Calu3 were maintained in regular growth medium and not subjected to treatment
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159355/suppl/GSM159355.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159355/suppl/GSM159355.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159356 | GPL96 |
|
Calu3-Parental_2
|
Calu3 human non-small lung cancer cells, parental (ATCC)
|
Morphology: epithelial, Organ: lung, Disease: adenocarcinoma (pleural effusion), Gender: male, Ethnicity: caucasian
|
parental Calu3 cells, no treatment
|
| Sample_geo_accession | GSM159356
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | American Type Culture Collection (ATCC)
| | Sample_treatment_protocol_ch1 | parental Calu3 were maintained in regular growth medium and not subjected to treatment
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159356/suppl/GSM159356.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159356/suppl/GSM159356.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159357 | GPL96 |
|
Calu3-Parental_3
|
Calu3 human non-small lung cancer cells, parental (ATCC)
|
Morphology: epithelial, Organ: lung, Disease: adenocarcinoma (pleural effusion), Gender: male, Ethnicity: caucasian
|
parental Calu3 cells, no treatment
|
| Sample_geo_accession | GSM159357
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | American Type Culture Collection (ATCC)
| | Sample_treatment_protocol_ch1 | parental Calu3 were maintained in regular growth medium and not subjected to treatment
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159357/suppl/GSM159357.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159357/suppl/GSM159357.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159358 | GPL96 |
|
Calu3-Parental_4
|
Calu3 human non-small lung cancer cells, parental (ATCC)
|
Morphology: epithelial, Organ: lung, Disease: adenocarcinoma (pleural effusion), Gender: male, Ethnicity: caucasian
|
parental Calu3 cells, no treatment
|
| Sample_geo_accession | GSM159358
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | American Type Culture Collection (ATCC)
| | Sample_treatment_protocol_ch1 | parental Calu3 were maintained in regular growth medium and not subjected to treatment
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159358/suppl/GSM159358.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159358/suppl/GSM159358.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159359 | GPL96 |
|
Calu3-GemR_Veh_1
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with vehicle (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159359
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated with vehicle in analogy to cultures treated with compounds
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159359/suppl/GSM159359.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159359/suppl/GSM159359.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159360 | GPL96 |
|
Calu3-GemR_Veh_2
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with vehicle (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159360
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated with vehicle in analogy to cultures treated with compounds
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159360/suppl/GSM159360.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159360/suppl/GSM159360.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159361 | GPL96 |
|
Calu3-GemR_Veh_3
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with vehicle (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159361
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated with vehicle in analogy to cultures treated with compounds
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159361/suppl/GSM159361.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159361/suppl/GSM159361.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159362 | GPL96 |
|
Calu3-GemR_Veh_4
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with vehicle (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159362
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated with vehicle in analogy to cultures treated with compounds
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159362/suppl/GSM159362.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159362/suppl/GSM159362.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159363 | GPL96 |
|
Calu3-GemR_B_1
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, resensitized to gemcitabine after treatment for 10 cycles of 10 days each with bexarotene
|
| Sample_geo_accession | GSM159363
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with continuous exposure to 1 micromolar bexarotene
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159363/suppl/GSM159363.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159363/suppl/GSM159363.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159364 | GPL96 |
|
Calu3-GemR_B_2
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, resensitized to gemcitabine after treatment for 10 cycles of 10 days each with bexarotene
|
| Sample_geo_accession | GSM159364
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with continuous exposure to 1 micromolar bexarotene
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159364/suppl/GSM159364.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159364/suppl/GSM159364.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159365 | GPL96 |
|
Calu3-GemR_B_3
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, resensitized to gemcitabine after treatment for 10 cycles of 10 days each with bexarotene
|
| Sample_geo_accession | GSM159365
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with continuous exposure to 1 micromolar bexarotene
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159365/suppl/GSM159365.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159365/suppl/GSM159365.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159366 | GPL96 |
|
Calu3-GemR_B_4
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, resensitized to gemcitabine after treatment for 10 cycles of 10 days each with bexarotene
|
| Sample_geo_accession | GSM159366
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with continuous exposure to 1 micromolar bexarotene
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159366/suppl/GSM159366.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159366/suppl/GSM159366.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159367 | GPL96 |
|
Calu3-GemR_G_1
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159367
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine for the first 3 days of the cycle followed by 7 days of vehicle
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159367/suppl/GSM159367.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159367/suppl/GSM159367.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159368 | GPL96 |
|
Calu3-GemR_G_2
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159368
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine for the first 3 days of the cycle followed by 7 days of vehicle
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159368/suppl/GSM159368.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159368/suppl/GSM159368.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159369 | GPL96 |
|
Calu3-GemR_G_3
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159369
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine for the first 3 days of the cycle followed by 7 days of vehicle
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159369/suppl/GSM159369.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159369/suppl/GSM159369.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159370 | GPL96 |
|
Calu3-GemR_G_4
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine (still gemcitabine resistant)
|
| Sample_geo_accession | GSM159370
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine for the first 3 days of the cycle followed by 7 days of vehicle
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159370/suppl/GSM159370.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159370/suppl/GSM159370.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159371 | GPL96 |
|
Calu3-GemR_G+B_1
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine plus bexarotene (still largely gemcitabine resistant since cells resensitized during culturing were eliminated from the culture by gemcitabine before harvest)
|
| Sample_geo_accession | GSM159371
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine and 1 micromolar bexarotene for the first 3 days of the cycle followed by 7 days of 1 micromolar bexarotene alone
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159371/suppl/GSM159371.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159371/suppl/GSM159371.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159372 | GPL96 |
|
Calu3-GemR_G+B_2
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine plus bexarotene (still largely gemcitabine resistant since cells resensitized during culturing were eliminated from the culture by gemcitabine before harvest)
|
| Sample_geo_accession | GSM159372
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine and 1 micromolar bexarotene for the first 3 days of the cycle followed by 7 days of 1 micromolar bexarotene alone
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159372/suppl/GSM159372.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159372/suppl/GSM159372.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159373 | GPL96 |
|
Calu3-GemR_G+B_3
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine plus bexarotene (still largely gemcitabine resistant since cells resensitized during culturing were eliminated from the culture by gemcitabine before harvest)
|
| Sample_geo_accession | GSM159373
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine and 1 micromolar bexarotene for the first 3 days of the cycle followed by 7 days of 1 micromolar bexarotene alone
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159373/suppl/GSM159373.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159373/suppl/GSM159373.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
GSM159374 | GPL96 |
|
Calu3-GemR_G+B_4
|
Calu3 human non-small lung cancer cells, gemcitabine resistant (Ligand)
|
gemcitabine resistant Calu3 derivative generated from the parental Calu3 line by consecutive treatments with 50 nM gemcitabine over a period of 3 months
|
gemcitabine resistant Calu3 cells, treated for 10 cycles of 10 days each with gemcitabine plus bexarotene (still largely gemcitabine resistant since cells resensitized during culturing were eliminated from the culture by gemcitabine before harvest)
|
| Sample_geo_accession | GSM159374
| | Sample_status | Public on Jan 31 2007
| | Sample_submission_date | Jan 30 2007
| | Sample_last_update_date | Jan 30 2007
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Ligand Pharmaceuticals, San Diego, CA
| | Sample_treatment_protocol_ch1 | gemcitabine resistant Calu3 were treated over 10 consecutive 10-day treatment cycles with 50 nM gemcitabine and 1 micromolar bexarotene for the first 3 days of the cycle followed by 7 days of 1 micromolar bexarotene alone
| | Sample_growth_protocol_ch1 | cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM glutamine in 95% air, 5% CO2
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Rneasy column (Qiagen) purification of total RNA was performed according to the manufacturer's instructions.
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 701021 Revision 4, Affymetrix).
| | Sample_hyb_protocol | Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human U133A Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
| | Sample_scan_protocol | GeneChips were scanned using the Affymetrix GeneArray scanner 2500.
| | Sample_data_processing | The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 250.
| | Sample_platform_id | GPL96
| | Sample_contact_name | Thomas,,Hermann
| | Sample_contact_email | thermann@ligand.com
| | Sample_contact_department | Molecular Oncology
| | Sample_contact_institute | Ligand Pharmaceuticals
| | Sample_contact_address | 10275 Science Center Dr.
| | Sample_contact_city | San Diego
| | Sample_contact_state | CA
| | Sample_contact_zip/postal_code | 92121
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159374/suppl/GSM159374.CEL.gz
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159374/suppl/GSM159374.EXP.gz
| | Sample_series_id | GSE6914
| | Sample_data_row_count | 22283
| | |
|
| |
| |
Make groups for comparisons |
(2 groups will be compared at a time) |
|
| Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|
